Howard Snow

Howard Snow has a diverse work experience in the pharmaceutical industry. Howard currently works for Sobi - Swedish Orphan Biovitrum AB (publ) as the Vice President and Head of Global Pharmacovigilance and Patient Safety. Prior to this role, they served as the Vice President and Global Head of Pharmacovigilance & Development Operations at Luzsana Biotechnology. In this position, they led a PV team and provided operational support for EU and US pharmacovigilance, engaged in safety oversight of clinical studies, and conducted clinical safety interactions with health authorities. Before joining Luzsana Biotechnology, Howard held various senior-level medical safety leadership roles at Novartis, where they led teams of safety physicians and scientists in studying the safety profile of development and marketed products. Howard has also worked at Bayer Pharmaceuticals as a Senior Director and Therapy Area Leader in Oncology Pharmacovigilance. Additionally, Howard has experience as a Global Drug Safety Physician at AstraZeneca and as a Global Safety Leader at Pfizer.

Howard Snow's education history is as follows:

- From 1989 to 1994, they attended Imperial College London, where they obtained their MBBS and BSc (Hons) degrees in Medicine.

- Between 2003 and 2005, they attended the Faculty of Pharmaceutical Medicine, earning the degree of FFPM.

- Howard also pursued a Master of Science (MSc) degree in Medical Toxicology at the University of Wales, Cardiff, though the specific dates are not provided.

- Howard Snow gained the MRCGP qualification from the Royal College of General Practitioners, but the time period is not mentioned.

In addition to their formal education, Howard Snow has obtained certifications in Difficult Situations: Solutions for Managers and Psychological Safety: Clear Blocks to Innovation, Collaboration, and Risk-Taking from LinkedIn, with the years of completion not stated.